Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: Results from clinical trials

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Isaacs, John D ^a   Zuckerman, Andrea ^b   Krishnaswami, Sriram ^b   Nduaka, Chudy ^b   Lan, Shuping ^b   Hutmacher, Matthew M ^c   Boy, Mary G ^b   Kowalski, Ken ^c   Menon, Sujatha ^b   Riese, Richard ^b  

^a The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^b PFIZER INC   (United States)

^c ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEHYDRATION; DERMATITIS; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84904519625     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4673     Document Type: Article

References (36)

1. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010, 7:41.
2. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, . ORAL Step investigators Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013, 381:451-460. ORAL Step investigators.
3. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, . ORAL Solo Investigators Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012, 367:495-507. ORAL Solo Investigators.
4. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garci´a Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, . ORAL Standard Investigators Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012, 367:508-519. ORAL Standard Investigators.
5. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova´ D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, . ORAL Scan Investigators Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013, 65:559-570. ORAL Scan Investigators.
6. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013, 159:253-261.
7. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF, . ORAL Start Investigators Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014, 370:2377-2386. ORAL Start Investigators.
8. Lawendy N, Krishnaswami S, Wang R, Gruben D, Cannon C, Swan S, Chan G. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol 2009, 49:423-429.
9. US Food and Drug Administration CfDEaR Pharmacology review of NDA, Xeljanz (tofacitinib). [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000PharmR.pdf], US Food and Drug Administration CfDEaR.
10. European Medicines Agency CfMPfHU European Public Assessment Report for Xeljanz, International non-proprietary name: tofacitinib. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002542/WC500154697.pdf], European Medicines Agency CfMPfHU.
11. Karstila K, Harmoinen AP, Lehtimaki TJ, Korpela MM, Mustonen JT, Saha HH. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance. Nephron Clin Pract 2008, 108:c284-c290.
12. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992, 38:1933-1953.
13. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
14. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012, 64:617-629.
15. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CAF, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60:1895-1905.
16. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012, 64:970-981.
17. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011, 63:1150-1158.
18. Tanaka Y, Takeuchi T, Yamanaka H, Suzuki M, Nakamura H, Toyoizumi S, Bradley J, Zwillich S. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week Phase 2b study [abstract]. Arthritis Rheum 2011, 63:S854.
19. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, Nduaka CI, Benda B, Gruben D, Nakamura H, Komuro Y, Zwillich SH, Wang L, Riese RJ. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014, 41:837-852.
20. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, De WM, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586.
21. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993, 21:457-478.
22. MedDRA Maintenance and Support Services Organization Introductory Guide to Standardised MedDRA Queries (SMQs) Version 13.1 2010, MSSO-DI-6226-13.1.0: 15-16, MedDRA Maintenance and Support Services Organization.
23. Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. Clin Pharm in Drug Dev 2014, Epub 23 May 2014; doi: 10.1002/cpdd.120.
24. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008, 36:205-216.
25. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995, 22:38-40.
26. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002, 46:2020-2028.
27. Vincenti F, Tedesco SH, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Shirley Lan SP, Kudlacz E, Krishnaswami S, Chan G. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 2012, 12:2446-2455.
28. Keystone E, Taylor P, Genovese MC, Schlichting D, Beattie S, Gaich C, Fidelus Gort R, Luchi M, Macias WL. 12-week results of a phase 2b dose-ranging study of LY3009104 (INCB028050), an oral Jak1/Jak2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2012, 71(Suppl 3):152-153.
29. Fleischmann R, Spencer-Green GT, Fan F, Frankovic B, Luo X, Hoock T, Damjanov N. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2011, 63:4041.
30. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008, 28:477-487.
31. Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994, 342:124-128.
32. Takahashi T, Shirasawa T, Miyake K, Yahagi Y, Maruyama N, Kasahara N, Kawamura T, Matsumura O, Mitarai T, Sakai O. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem Biophys Res Commun 1995, 209:218-226.
33. Arany I, Megyesi JK, Nelkin BD, Safirstein RL. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006, 70:669-674.
34. Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005, 175:4236-4246.
35. Lee YH, Choi SJ, Ji JD, Song GG. Serum creatine kinase in patients with rheumatic diseases. Clin Rheumatol 2000, 19:296-300.
36. Brezis M, Rosen S, Epstein FH. Acute Renal Failure. In the Kidney 1986, 735-747. Philadelphia: W.B. Saunders Company, Brenner BM, Rector FC, 1.